Does the media refer more to EYPT or HROW?

In the previous week, Harrow had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 2 mentions for Harrow and 1 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Harrow's score of 0.06 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AVLN or EYPT?

In the previous week, Avalyn Pharma had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 2 mentions for Avalyn Pharma and 1 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Avalyn Pharma's score of 0.06 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EYPT or ANRO?

In the previous week, Alto Neuroscience had 2 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Alto Neuroscience and 1 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Alto Neuroscience's score of 0.65 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EYPT or SPTX?

In the previous week, Seaport Therapeutics had 6 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 7 mentions for Seaport Therapeutics and 1 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Seaport Therapeutics' score of 0.21 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seaport Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eyepoint Pharmaceuticals (EYPT) Competitors

$2.99 -0.15 (-4.78%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$3.08 +0.09 (+3.14%)

As of 10/16/2026 07:52 PM Eastern

Compare

EYPT vs. HROW, AVLN, ANRO, TBPH, and SPTX

Should you buy Eyepoint Pharmaceuticals stock or one of its competitors? Eyepoint Pharmaceuticals's main competitors and comparable companies include Harrow (HROW), Avalyn Pharma (AVLN), Alto Neuroscience (ANRO), Theravance Biopharma (TBPH), and Seaport Therapeutics (SPTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eyepoint Pharmaceuticals compare to Harrow?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Harrow (NASDAQ:HROW) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Eyepoint Pharmaceuticals presently has a consensus target price of $25.70, suggesting a potential upside of 759.53%. Harrow has a consensus target price of $66.17, suggesting a potential upside of 142.55%. Given Eyepoint Pharmaceuticals' higher probable upside, equities research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Harrow	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Harrow had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 2 mentions for Harrow and 1 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Harrow's score of 0.06 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harrow has higher revenue and earnings than Eyepoint Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.22	-$231.96M	-$3.74	N/A
Harrow	$272.30M	3.76	-$5.14M	-$1.00	N/A

Harrow has a net margin of -13.51% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Harrow's return on equity of -38.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Harrow	-13.51%	-38.00%	-3.37%

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Harrow has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Harrow beats Eyepoint Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Avalyn Pharma currently has a consensus target price of $60.00, indicating a potential upside of 153.59%. Eyepoint Pharmaceuticals has a consensus target price of $25.70, indicating a potential upside of 759.53%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Avalyn Pharma has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Avalyn Pharma is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
Eyepoint Pharmaceuticals	$31.37M	8.22	-$231.96M	-$3.74	N/A

In the previous week, Avalyn Pharma had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 2 mentions for Avalyn Pharma and 1 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Avalyn Pharma's score of 0.06 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Avalyn Pharma's return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Summary

Eyepoint Pharmaceuticals beats Avalyn Pharma on 8 of the 14 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alto Neuroscience has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Alto Neuroscience's return on equity of -46.46% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Alto Neuroscience	N/A	-46.46%	-39.09%

In the previous week, Alto Neuroscience had 2 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Alto Neuroscience and 1 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Alto Neuroscience's score of 0.65 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Alto Neuroscience has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Alto Neuroscience is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.22	-$231.96M	-$3.74	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Eyepoint Pharmaceuticals presently has a consensus target price of $25.70, indicating a potential upside of 759.53%. Alto Neuroscience has a consensus target price of $37.25, indicating a potential upside of 69.37%. Given Eyepoint Pharmaceuticals' higher probable upside, equities analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Alto Neuroscience beats Eyepoint Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 1 mentions for Eyepoint Pharmaceuticals and 0 mentions for Theravance Biopharma. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Theravance Biopharma's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Theravance Biopharma	Neutral
Eyepoint Pharmaceuticals	Positive

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Theravance Biopharma has a net margin of 51.58% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Theravance Biopharma's return on equity of -0.77% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Theravance Biopharma presently has a consensus target price of $19.40, suggesting a potential upside of 13.92%. Eyepoint Pharmaceuticals has a consensus target price of $25.70, suggesting a potential upside of 759.53%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Theravance Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

Theravance Biopharma has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86
Eyepoint Pharmaceuticals	$31.37M	8.22	-$231.96M	-$3.74	N/A

Summary

Theravance Biopharma beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Seaport Therapeutics?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Seaport Therapeutics (NASDAQ:SPTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, suggesting a potential upside of 759.53%. Seaport Therapeutics has a consensus price target of $37.25, suggesting a potential upside of 108.92%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Seaport Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Seaport Therapeutics has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.22	-$231.96M	-$3.74	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Seaport Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Seaport Therapeutics' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Seaport Therapeutics	N/A	N/A	N/A

In the previous week, Seaport Therapeutics had 6 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 7 mentions for Seaport Therapeutics and 1 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.94 beat Seaport Therapeutics' score of 0.21 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seaport Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Seaport Therapeutics beats Eyepoint Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EYPT vs. The Competition

Export

Metric	Eyepoint Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$257.77M	$12.78B	$7.44B	$12.68B
Dividend Yield	N/A	2.60%	2.50%	32.09%
P/E Ratio	-0.80	620.71	194.37	19.23
Price / Sales	8.22	745.29	570.76	76.91
Price / Cash	N/A	80.22	74.88	50.51
Price / Book	0.81	9.21	10.31	5.85
Net Income	-$231.96M	$2.85B	$3.51B	$381.63M
7 Day Performance	-12.06%	-5.25%	-5.47%	-5.04%
1 Month Performance	-25.06%	-9.18%	-9.66%	-7.99%
1 Year Performance	-74.29%	-6.07%	0.73%	-5.68%

Eyepoint Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EYPT Eyepoint Pharmaceuticals	2.6341 of 5 stars	$2.99 -4.8%	$25.70 +759.5%	-74.1%	$257.77M	$31.37M	N/A	214
HROW Harrow	2.1076 of 5 stars	$28.37 -2.5%	$66.17 +133.2%	-28.1%	$1.06B	$272.30M	N/A	373	News Coverage
AVLN Avalyn Pharma	2.1736 of 5 stars	$23.08 -6.9%	$60.00 +160.0%	N/A	$1.02B	N/A	N/A	55
ANRO Alto Neuroscience	2.742 of 5 stars	$22.85 -5.4%	$37.25 +63.0%	+276.6%	$894.52M	N/A	N/A	68	News Coverage
TBPH Theravance Biopharma	2.4276 of 5 stars	$17.03 flat	$19.40 +13.9%	N/A	$884.18M	$104.31M	16.86	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. HROW, AVLN, ANRO, TBPH, and SPTX

How does Eyepoint Pharmaceuticals compare to Harrow?

Summary

How does Eyepoint Pharmaceuticals compare to Avalyn Pharma?

Summary

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Summary

How does Eyepoint Pharmaceuticals compare to Theravance Biopharma?

Summary

How does Eyepoint Pharmaceuticals compare to Seaport Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. HROW, AVLN, ANRO, TBPH, and SPTX

How does Eyepoint Pharmaceuticals compare to Harrow?

Do analysts rate EYPT or HROW?

Does the media refer more to EYPT or HROW?

Which has better valuation and earnings, EYPT or HROW?

Is EYPT or HROW more profitable?

Which has more risk & volatility, EYPT or HROW?

Do institutionals and insiders hold more shares of EYPT or HROW?

Summary

How does Eyepoint Pharmaceuticals compare to Avalyn Pharma?

Do insiders & institutionals believe in AVLN or EYPT?

Do analysts recommend AVLN or EYPT?

Which has higher earnings and valuation, AVLN or EYPT?

Does the media refer more to AVLN or EYPT?

Is AVLN or EYPT more profitable?

Summary

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Do insiders and institutionals believe in EYPT or ANRO?

Is EYPT or ANRO more profitable?

Does the media favor EYPT or ANRO?

Which has more risk & volatility, EYPT or ANRO?

Which has stronger earnings and valuation, EYPT or ANRO?

Do analysts recommend EYPT or ANRO?

Summary

How does Eyepoint Pharmaceuticals compare to Theravance Biopharma?

Does the media refer more to TBPH or EYPT?

Do institutionals and insiders hold more shares of TBPH or EYPT?

Is TBPH or EYPT more profitable?

Do analysts recommend TBPH or EYPT?

Which has more risk & volatility, TBPH or EYPT?

Which has preferable earnings & valuation, TBPH or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Seaport Therapeutics?

Do analysts recommend EYPT or SPTX?

Which has preferable earnings & valuation, EYPT or SPTX?

Do insiders & institutionals have more ownership in EYPT or SPTX?

Is EYPT or SPTX more profitable?

Does the media favor EYPT or SPTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools